Abstract | BACKGROUND: Systemic chemotherapies are associated with limited response rates and significant toxicity in patients with malignant digestive endocrine tumors ( DET). Preliminary studies have reported interesting results with temozolomide in patients with DET. AIM: It was the aim of this study to assess the efficacy and safety of temozolomide in patients with malignant DET. PATIENTS AND METHODS: Twenty-one patients, median age 61 years (range 56-77), with metastatic well-differentiated DET were retrospectively studied. All patients except 1 had received prior treatment (hepatic resection, chemotherapy). All patients had progressive disease in the 3 months prior to entry into the study. Temozolomide was administered at doses of 200 mg/m(2) daily for 5 days, every 28 days. Treatment was assessed for safety, progression-free and overall survival. RESULTS: The median number of temozolomide cycles was 5 (range 2-15). Grade 3 hematological toxicity occurred in 5 patients. There were no toxic deaths. According to the Response Evaluation Criteria in Solid Tumors criteria, partial response and stabilization were obtained in 1 (5%) and 17 patients (81%), respectively. The median time to progression was 9 months (range 3-26). The 1-year progression-free survival and overall survival were 42 and 77%, respectively. CONCLUSION:
Temozolomide is a well-tolerated oral chemotherapy in patients with malignant DET, including those who have already received treatment. In patients with progressive disease, temozolomide controls tumor progression in 86% of cases.
|
Authors | Frédérique Maire, Pascal Hammel, Sandrine Faivre, Olivia Hentic, Lorena Yapur, Béatrice Larroque, Anne Couvelard, Magaly Zappa, Eric Raymond, Philippe Lévy, Philippe Ruszniewski |
Journal | Neuroendocrinology
(Neuroendocrinology)
Vol. 90
Issue 1
Pg. 67-72
( 2009)
ISSN: 1423-0194 [Electronic] Switzerland |
PMID | 19521065
(Publication Type: Journal Article)
|
Copyright | 2009 S. Karger AG, Basel. |
Chemical References |
- Antineoplastic Agents, Alkylating
- Dacarbazine
- Temozolomide
|
Topics |
- Aged
- Analysis of Variance
- Antineoplastic Agents, Alkylating
(adverse effects, therapeutic use)
- Carcinoid Tumor
(drug therapy)
- Dacarbazine
(adverse effects, analogs & derivatives, therapeutic use)
- Digestive System Neoplasms
(drug therapy, mortality)
- Disease Progression
- Endocrine Gland Neoplasms
(drug therapy, mortality)
- Female
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Retrospective Studies
- Temozolomide
- Time Factors
- Treatment Outcome
|